Development of a novel lateral flow immunoassay shows improved reproducibility and stability over time, indicating potential for point-of-care applications.
Lateral flow immunoassays (LFIAs) coupled to surface enhanced Raman scattering (SERS) measurements can produce quantitative outputs with excellent sensitivity. Despite this, they have not been adopted into point-of-care (POC) scenarios,...
No takes yet. Share an insight, caveat, or question.
Sloan-Dennison et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: